Ergoteles’s Medpace MEDP Stock Holding History

Ergoteles’s Portfolio MEDP Stock Details MEDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-33,365	Closed	-$8.01M	–	525
2023 Q2	$8.01M	Buy	+33,365	New	+$6.93M	0.38%	55
2022 Q4	–	Sell	-30,188	Closed	-$4.75M	–	1715
2022 Q3	$4.75M	Buy	30,188 +12,999	+76%	+$2.07M	0.17%	124
2022 Q2	$2.57M	Buy	17,189 +12,916	+302%	+$1.87M	0.08%	257
2022 Q1	$699K	Buy	4,273 +2,666	+166%	+$440K	0.03%	546
2021 Q4	$350K	Buy	+1,607	New	+$337K	0.01%	791

Other funds holding MEDP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ergoteles's MEDP Position: Q3 2023 in Review

Ergoteles sold out of Medpace (MEDP) in Q3 2023, closing a stake of 33,365 shares — an estimated $8.01M sold.

Ergoteles first reported a position in MEDP in Q4 2021 and held it in 5 quarters. The position peaked at $8.01M in Q2 2023. 488 funds tracked by Wall St. Rank hold MEDP as of Q3 2023.

Ergoteles reported no remaining Medpace position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 33,365 Medpace shares in Q3 2023, an estimated $8.01M.
Ergoteles first reported a position in Medpace in Q4 2021 and held it in 5 quarters.
Ergoteles's Medpace position peaked at $8.01M in Q2 2023.
488 funds tracked by Wall St. Rank held Medpace as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.